KR102778328B1 - 유전체 편집 효율 증가를 위한 화합물 - Google Patents

유전체 편집 효율 증가를 위한 화합물 Download PDF

Info

Publication number
KR102778328B1
KR102778328B1 KR1020237017487A KR20237017487A KR102778328B1 KR 102778328 B1 KR102778328 B1 KR 102778328B1 KR 1020237017487 A KR1020237017487 A KR 1020237017487A KR 20237017487 A KR20237017487 A KR 20237017487A KR 102778328 B1 KR102778328 B1 KR 102778328B1
Authority
KR
South Korea
Prior art keywords
dna
compound
target cell
cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237017487A
Other languages
English (en)
Korean (ko)
Other versions
KR20230084312A (ko
Inventor
스테판 리센버그
토미스라브 마리칙
Original Assignee
막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP17165784.4A external-priority patent/EP3388517A1/en
Priority claimed from EP17203591.7A external-priority patent/EP3489357A1/en
Application filed by 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. filed Critical 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우.
Publication of KR20230084312A publication Critical patent/KR20230084312A/ko
Application granted granted Critical
Publication of KR102778328B1 publication Critical patent/KR102778328B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrane Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020237017487A 2017-04-10 2018-04-10 유전체 편집 효율 증가를 위한 화합물 Active KR102778328B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP17165784.4A EP3388517A1 (en) 2017-04-10 2017-04-10 Compounds for increasing genome editing efficiency
EP17165784.4 2017-04-10
EP17203591.7A EP3489357A1 (en) 2017-11-24 2017-11-24 Compounds for increasing genome editing efficiency
EP17203591.7 2017-11-24
PCT/EP2018/059173 WO2018189186A1 (en) 2017-04-10 2018-04-10 Compounds for increasing genome editing efficiency
KR1020197032518A KR102537447B1 (ko) 2017-04-10 2018-04-10 유전체 편집 효율 증가를 위한 화합물

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197032518A Division KR102537447B1 (ko) 2017-04-10 2018-04-10 유전체 편집 효율 증가를 위한 화합물

Publications (2)

Publication Number Publication Date
KR20230084312A KR20230084312A (ko) 2023-06-12
KR102778328B1 true KR102778328B1 (ko) 2025-03-11

Family

ID=62116381

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237017487A Active KR102778328B1 (ko) 2017-04-10 2018-04-10 유전체 편집 효율 증가를 위한 화합물
KR1020197032518A Active KR102537447B1 (ko) 2017-04-10 2018-04-10 유전체 편집 효율 증가를 위한 화합물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197032518A Active KR102537447B1 (ko) 2017-04-10 2018-04-10 유전체 편집 효율 증가를 위한 화합물

Country Status (9)

Country Link
US (1) US12173309B2 (cg-RX-API-DMAC7.html)
EP (1) EP3610008A1 (cg-RX-API-DMAC7.html)
JP (2) JP7319194B2 (cg-RX-API-DMAC7.html)
KR (2) KR102778328B1 (cg-RX-API-DMAC7.html)
CN (1) CN110691848B (cg-RX-API-DMAC7.html)
CA (1) CA3058697A1 (cg-RX-API-DMAC7.html)
IL (1) IL269887B2 (cg-RX-API-DMAC7.html)
SG (1) SG11201909432SA (cg-RX-API-DMAC7.html)
WO (1) WO2018189186A1 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020534813A (ja) * 2017-09-08 2020-12-03 ライフ テクノロジーズ コーポレイション 改良された相同組換えおよびその組成物のための方法
JP7235153B2 (ja) * 2017-12-29 2023-03-08 株式会社三洋物産 遊技機
BR112020014140A2 (pt) * 2018-01-17 2020-12-01 Vertex Pharmaceuticals Incorporated inibidores de dna-pk
US12269804B2 (en) 2018-01-17 2025-04-08 Vertex Pharmaceuticals Incorporated Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency
JP7235154B2 (ja) * 2018-02-15 2023-03-08 株式会社三洋物産 遊技機
JP7231076B2 (ja) * 2018-03-08 2023-03-01 株式会社三洋物産 遊技機
CA3128085A1 (en) 2018-12-21 2020-06-25 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Dna-pkcs inhibitors for increasing genome editing efficiency
JP2020103418A (ja) * 2018-12-26 2020-07-09 株式会社三洋物産 遊技機
JP2020130466A (ja) * 2019-02-15 2020-08-31 株式会社三洋物産 遊技機
JP7234740B2 (ja) * 2019-03-28 2023-03-08 株式会社三洋物産 遊技機
JP7234741B2 (ja) * 2019-03-28 2023-03-08 株式会社三洋物産 遊技機
JP7234760B2 (ja) * 2019-04-11 2023-03-08 株式会社三洋物産 遊技機
JP7234761B2 (ja) * 2019-04-11 2023-03-08 株式会社三洋物産 遊技機
JP2021186294A (ja) * 2020-05-29 2021-12-13 株式会社三洋物産 遊技機
CN112359065B (zh) * 2020-09-21 2023-04-07 中国医学科学院血液病医院(中国医学科学院血液学研究所) 一种提高基因敲入效率的小分子组合物
KR102545913B1 (ko) * 2021-02-02 2023-06-22 재단법인 아산사회복지재단 히스톤 탈아세틸화 억제제를 포함하는 염기교정 기술의 효율성 및 정확도 향상용 조성물 및 이의 용도
CA3220253A1 (en) * 2021-05-24 2022-12-01 Neville E. SANJANA Compositions and methods for increasing efficiency of precise editing repair
CN113403309B (zh) * 2021-05-24 2022-08-16 珠海舒桐医疗科技有限公司 非同源双链寡聚核苷酸片段在基因敲除系统中的应用
EP4095246A1 (en) 2021-05-27 2022-11-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel crispr grnas
US20230070047A1 (en) * 2021-07-06 2023-03-09 Regents Of The University Of Minnesota Method to enhance gene editing
JP2023105108A (ja) * 2021-10-27 2023-07-28 株式会社三洋物産 遊技機
JP2023105111A (ja) * 2021-10-27 2023-07-28 株式会社三洋物産 遊技機
JP2023105110A (ja) * 2021-10-27 2023-07-28 株式会社三洋物産 遊技機
JP2023063369A (ja) * 2022-01-07 2023-05-09 株式会社三洋物産 遊技機
JP2023053387A (ja) * 2022-02-04 2023-04-12 株式会社三洋物産 遊技機
JP2023060269A (ja) * 2022-04-01 2023-04-27 株式会社三洋物産 遊技機
JP2023060270A (ja) * 2022-04-01 2023-04-27 株式会社三洋物産 遊技機
CN114717207B (zh) * 2022-04-25 2023-03-07 苏州泓迅生物科技股份有限公司 一种酵母细胞同源重组酶系、dna体外组装试剂及其应用
WO2025212548A1 (en) 2024-04-02 2025-10-09 Sigma-Aldrich Co. Llc Methods and compositions for improvement of base editor and homology directed repair genome editing outcomes
WO2026005012A1 (ja) * 2024-06-28 2026-01-02 学校法人自治医科大学 インビトロ及びインビボのゲノム編集における相同組換えの効率を高める方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016509063A (ja) * 2013-02-25 2016-03-24 サンガモ バイオサイエンシーズ, インコーポレイテッド ヌクレアーゼ媒介性遺伝子破壊を増強するための方法および組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013188881A1 (en) 2012-06-15 2013-12-19 President And Fellows Of Harvard College Compounds, compositions and methods for treating or preventing neurodegenerative disorders
JP6738728B2 (ja) * 2013-06-17 2020-08-19 ザ・ブロード・インスティテュート・インコーポレイテッド 肝臓ターゲティングおよび治療のためのCRISPR−Cas系、ベクターおよび組成物の送達および使用
ES2730378T3 (es) * 2014-08-27 2019-11-11 Caribou Biosciences Inc Procedimientos para incrementar la eficiencia de la modificación mediada por Cas9
WO2016073990A2 (en) * 2014-11-07 2016-05-12 Editas Medicine, Inc. Methods for improving crispr/cas-mediated genome-editing

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016509063A (ja) * 2013-02-25 2016-03-24 サンガモ バイオサイエンシーズ, インコーポレイテッド ヌクレアーゼ媒介性遺伝子破壊を増強するための方法および組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Francis Robert et al, "Pharmacological inhibition of DNA-PK stimulates Cas9-mediated genome editing", Genome Medicine, Vol. 7, Article number 93(2015.08.)*
J Immunol. 2016 April 1; 196(7): 3032-3042

Also Published As

Publication number Publication date
KR20230084312A (ko) 2023-06-12
US12173309B2 (en) 2024-12-24
SG11201909432SA (en) 2019-11-28
JP7319194B2 (ja) 2023-08-01
CN110691848B (zh) 2024-04-02
JP7795493B2 (ja) 2026-01-07
EP3610008A1 (en) 2020-02-19
WO2018189186A1 (en) 2018-10-18
JP2023093479A (ja) 2023-07-04
CA3058697A1 (en) 2018-10-18
US20200392540A1 (en) 2020-12-17
CN110691848A (zh) 2020-01-14
JP2020516258A (ja) 2020-06-11
IL269887B1 (en) 2024-09-01
KR102537447B1 (ko) 2023-05-30
KR20190139239A (ko) 2019-12-17
IL269887A (en) 2019-11-28
IL269887B2 (en) 2025-01-01

Similar Documents

Publication Publication Date Title
JP7795493B2 (ja) ゲノム編集効率を増大させるための化合物
JP6993063B2 (ja) ゲノムエンジニアリング
EP3388517A1 (en) Compounds for increasing genome editing efficiency
EP3911330B1 (en) Dna-pkcs inhibitors for increasing genome editing efficiency
US20180023139A1 (en) Methods of identifying essential protein domains
JP2019500043A (ja) 異常ヘモグロビン症の治療用組成物および方法
Zhang et al. A high-throughput small molecule screen identifies farrerol as a potentiator of CRISPR/Cas9-mediated genome editing
US12286624B2 (en) Method for generating a gene editing vector with fixed guide RNA pairs
EP3489357A1 (en) Compounds for increasing genome editing efficiency
US20250122538A1 (en) Compounds for Increasing Genome Editing Efficiency
US20240010991A1 (en) Materials and methods for bioengineered ipsc populations
AU2024334482C1 (en) Methods and compositions for engineered da neuronal cells
Elton et al. Maximizing the efficacy of CRISPR/Cas homology-directed repair gene targeting
Riesenberg Methods to increase the efficiency of precise CRISPR genome editing
KR102404828B1 (ko) 미분화 만능 줄기세포로부터 유전자 편집된 세포의 선별 방법
Ionasz Elucidating the role of transcription in recurrent DNA break formation
Xuemeng Characterizing the Regulation and Function of Endogenous Retroviruses in Mammalian Pluripotent Cells
Savic DEVELOPING A CLINCALLY RELEVANT ISOGENIC CELL LINE OF HUNTINGTON’S DISEASE
Vered Analysis of translesion DNA synthesis in embryonic stem cells

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000